The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

“end-stage renal disease,” or “end-stage kidney disease” when talking about kidney failure. In lupus nephritis, the inflammation caused by lupus damages your kidneys. Over time, this damage can cause ...

In a new study published in Lupus Science & Medicine, researchers found a connection between renal (kidney) response and long ...

ACR 2024 highlighted new guidelines for the screening, treatment, and management of lupus nephritis, stressing prompt kidney biopsy and timely treatment.

However, some 40% of patients were insulin users. Within 1 year after SLE diagnosis, the main outcomes -- lupus nephritis, ...

lupus nephritis (LN), characterized by immune system induced inflammation of the kidneys. Within 10 years, up to 20% of LN patients progress to end-stage renal disease, a potentially fatal ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

Lupus Nephritis Emerging Drugs Chapters This segment of the Lupus Nephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, ...

Isotopia is proud to announce a groundbreaking partnership with LIVEKIDNEY.BIO, a clinical-stage biotech innovator, to ...

GLP-1 RAs might lower kidney failure risk in patients with lupus nephritis by reducing pro-inflammatory mediators. Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with ...

LIVEKIDNEY.BIO is a clinical-stage biotech company focused on developing innovative therapeutic solutions for kidney diseases, particularly lupus nephritis. Through advanced research and cutting ...